{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:04:14Z","timestamp":1783008254404,"version":"3.54.5"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T00:00:00Z","timestamp":1542585600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s00059-018-4764-5","type":"journal-article","created":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T12:13:59Z","timestamp":1542629639000},"page":"689-694","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["ESC\/EACTS-Leitlinien zur Myokardrevaskularisation 2018","ESC\/EACTS guidelines on myocardial revascularization 2018"],"prefix":"10.1007","volume":"43","author":[{"given":"F.-J.","family":"Neumann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Hochholzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Siepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,19]]},"reference":[{"key":"4764_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy394","author":"FJ Neumann","year":"2018","unstructured":"Neumann FJ, Sousa-Uva M, Ahlsson A et al (2018) 2018 ESC\/EACTS guidelines on myocardial revascularization. Eur Heart\u00a0J. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehy394","journal-title":"Eur Heart J"},{"key":"4764_CR2","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.jacc.2013.05.033","volume":"62","author":"S Garcia","year":"2013","unstructured":"Garcia S, Sandoval Y, Roukoz H et al (2013) Outcomes after complete versus incomplete revascularization of patients with multivessel coronary artery disease: a meta-analysis of 89,883 patients enrolled in randomized clinical trials and observational studies. J\u00a0Am Coll Cardiol 62:1421\u20131431","journal-title":"J Am Coll Cardiol"},{"key":"4764_CR3","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(18)30423-9","volume":"391","author":"SJ Head","year":"2018","unstructured":"Head SJ, Milojevic M, Daemen J et\u00a0al (2018) Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet 391:939\u20139484","journal-title":"Lancet"},{"key":"4764_CR4","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/S0140-6736(18)31779-3","volume":"392","author":"SJ Head","year":"2018","unstructured":"Head SJ, Papageorgiou G, Milojevic M et\u00a0al (2018) Interpretation of results of pooled analysis of individual patient data\u2014authors\u2019 reply. Lancet 392:818","journal-title":"Lancet"},{"key":"4764_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy532","author":"S Windecker","year":"2018","unstructured":"Windecker S, Neumann FJ, Juni P et\u00a0al (2018) Considerations for the choice between coronary artery bypass grafting and percutaneous coronary intervention as revascularization strategies in major categories of patients with stable multivessel coronary artery disease: an accompanying article of the task force of the 2018 ESC\/EACTS guidelines on myocardial revascularization. Eur Heart\u00a0J. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehy532","journal-title":"Eur Heart J"},{"key":"4764_CR6","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa1710261","volume":"377","author":"H Thiele","year":"2017","unstructured":"Thiele H, Akin I, Sandri M et\u00a0al (2017) PCI strategies in patients with acute myocardial infarction and cardiogenic shock. N\u00a0Engl J Med 377:2419\u20132432","journal-title":"N Engl J Med"},{"key":"4764_CR7","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJMoa1602001","volume":"374","author":"EJ Velazquez","year":"2016","unstructured":"Velazquez EJ, Lee KL, Jones RH et al (2016) Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N\u00a0Engl J Med 374:1511\u20131520","journal-title":"N Engl J Med"},{"key":"4764_CR8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"M Valgimigli","year":"2018","unstructured":"Valgimigli M, Bueno H, Byrne RA et\u00a0al (2018) 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart\u00a0J 39:213\u2013260","journal-title":"Eur Heart J"},{"key":"4764_CR9","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","volume":"390","author":"D Sibbing","year":"2017","unstructured":"Sibbing D, Aradi D, Jacobshagen C et al (2017) Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): A randomised, open-label, multicentre trial. Lancet 390:1747\u20131757","journal-title":"Lancet"}],"container-title":["Herz"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-018-4764-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-018-4764-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-018-4764-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T00:53:18Z","timestamp":1574124798000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-018-4764-5"}},"subtitle":["Die wichtigsten Neuerungen","The most important innovations"],"short-title":[],"issued":{"date-parts":[[2018,11,19]]},"references-count":9,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4764"],"URL":"https:\/\/doi.org\/10.1007\/s00059-018-4764-5","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,19]]},"assertion":[{"value":"19 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F.\u2011J.\u00a0Neumann berichtet, dass sein Arbeitgeber Forschungsunterst\u00fctzung sowie Berater- und Vortragshonorare von Daiichi Sankyo, Astra Zeneca, Sanofi-Aventis, Bayer, The Medicines Company, Bristol, Novartis, Roche, Boston Scientific, Biotronik, Medtronic, Edwards und Ferrer erhalten hat. W.\u00a0Hochholzer berichtet Berater- und Vortragshonorare von AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo und The Medicines Company. M.\u00a0Siepe gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}